Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Kabco to stop production until GMPs met; ginkgo is not a food additive, FDA warns; more spiked sexual enhancement supplements recalled; SmartShield expands civilian distribution; P&G advances toward zero-waste goals; Sanofi opens Vietnam facility; Carlson doubles capacity.

You may also be interested in...



FDA War On Tainted Supplements Wages On

A warning letter about tainted dietary supplements is a reminder that even though recalls of spiked supplements are declining, products marketed as supplements that contain undeclared prescription drugs still infiltrate the market. The letter illustrates recalling tainted supplements may not prevent future enforcement actions.

New Products In Brief

BASF’s Tonalin CLA helps Muscle Milk “evolve”; Fiber One bars add protein; Sustamine fortifies Invigorate sports drink; Carlson boosts sulfur, bone support supplements; Yummi Bears go sugar-free; RightSize downsizes into single-serve smoothie packs; more New Products In Brief.

Basic GMP Failures Will Prompt Heightened FDA Scrutiny

FDA supplement programs director Dan Fabricant and food and drug law attorney Marc Ullman reflect on the ongoing struggles of many supplement firms to meet good manufacturing practice standards. “‘I don’t have the resources to comply’ is not an excuse. Then get out of the business,” Ullman says.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel